[go: up one dir, main page]

MXPA02002772A - Virus oncolitico. - Google Patents

Virus oncolitico.

Info

Publication number
MXPA02002772A
MXPA02002772A MXPA02002772A MXPA02002772A MXPA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A
Authority
MX
Mexico
Prior art keywords
virus
tumor cell
pkr
stat1
oncolytic virus
Prior art date
Application number
MXPA02002772A
Other languages
English (en)
Inventor
Cameron Bell John
Original Assignee
Pro Virus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Virus Inc filed Critical Pro Virus Inc
Publication of MXPA02002772A publication Critical patent/MXPA02002772A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

La presente invencion se dirige a un metodo para reducir la viabilidad de una celula de tumor que implica administrar un virus que no es un patogeno humano comun a la celula de tumor. Preferiblemente, el virus exhibe susceptibilidad diferencial, porque las celulas normales no son afectadas por el virus. Esta susceptibilidad diferencial es mas pronunciada en la presencia de interferon. La celula de tumor se caracteriza por tener niveles bajos, o no tener, actividad PKR, o por ser PKR-/-, STATI-/- o tanto PKR-/- como STAT1-/-. El virus se selecciona del grupo que consiste en Rabdovirus y picornavirus, y preferiblemente es el virus de estomatitis vesicular (VSV) o un derivado del mismo.
MXPA02002772A 1999-09-17 2000-09-18 Virus oncolitico. MXPA02002772A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39787399A 1999-09-17 1999-09-17
PCT/US2000/025510 WO2001019380A2 (en) 1999-09-17 2000-09-18 Oncolytic virus

Publications (1)

Publication Number Publication Date
MXPA02002772A true MXPA02002772A (es) 2004-04-02

Family

ID=23573018

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002772A MXPA02002772A (es) 1999-09-17 2000-09-18 Virus oncolitico.

Country Status (13)

Country Link
EP (2) EP1716858B9 (es)
JP (1) JP5060694B2 (es)
CN (1) CN1289098C (es)
AT (2) ATE418341T1 (es)
AU (1) AU782402B2 (es)
CA (1) CA2386920C (es)
DE (2) DE60041210D1 (es)
ES (2) ES2260057T3 (es)
HK (1) HK1044708B (es)
IL (2) IL148621A0 (es)
MX (1) MXPA02002772A (es)
NZ (4) NZ517573A (es)
WO (1) WO2001019380A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
JP5208343B2 (ja) 2000-06-26 2013-06-12 ウェルスタット バイオロジクス コーポレイション ウイルスを用いる細胞の浄化
HUP0400882A3 (en) 2001-05-11 2011-01-28 Wellstat Biologics Corp Oncolytic virus therapy
US20030044386A1 (en) * 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
AU2008201293B2 (en) * 2001-07-11 2011-08-18 University Of Miami Recombinant VSV for the treatment of tumor cells
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
WO2004085658A1 (en) 2003-03-27 2004-10-07 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
CA2568772A1 (en) 2004-06-01 2005-12-15 San Diego State University Foundation Expression system based on recombinant vesicular stomatitis virus synthesizing t7 rna polymerase
CN101065144B (zh) * 2004-08-20 2012-06-13 溶瘤病毒有限公司 治疗血液癌症的方法和组合物
EP1793851B1 (en) 2004-08-20 2016-10-05 Viralytics Limited Methods and compositions for treatment of hematologic cancers
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
CA2617600A1 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
EP2064229B1 (en) * 2006-09-15 2015-08-12 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
JP2011507523A (ja) * 2007-12-21 2011-03-10 ワイス・エルエルシー 遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法
EP2349296B1 (en) * 2008-08-21 2017-04-05 Ottawa Hospital Research Institute Engineered synergistic oncolytic viral symbiosis
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
CA2755790A1 (en) 2009-03-16 2010-09-23 Mcmaster University Vaccination methods
CN102858959B (zh) * 2009-12-10 2016-02-24 渥太华医院研究院 溶瘤弹状病毒
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
ES2545357T3 (es) * 2010-09-02 2015-09-10 Mayo Foundation For Medical Education And Research Virus de la estomatitis vesicular
EP2718427B1 (en) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Compositions for glioblastoma treatment
US20140335117A1 (en) 2011-10-07 2014-11-13 Skau Aps Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
EP2958994B1 (en) 2013-02-21 2019-05-29 Turnstone Limited Partnership Vaccine composition
PL2983706T3 (pl) 2013-04-10 2021-11-02 Isd Immunotech Aps Zastosowanie domen tłumiących układ immunologiczny jako leków
WO2014198003A1 (en) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute Compositions and methods for enhancing virus replication
PL2826856T3 (pl) * 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
US11015229B2 (en) 2014-07-21 2021-05-25 Novellusdx Ltd. Methods and systems for determining oncogenic index of patient specific mutations
CN105233285B (zh) * 2015-09-06 2018-10-12 广州威溶特医药科技有限公司 Epac直接或间接激动剂与溶瘤病毒的联合应用
CN110636853B (zh) 2017-05-19 2024-10-18 佐治亚州立大学研究基金会公司 重组溶瘤病毒
US10610583B2 (en) 2017-08-31 2020-04-07 Regents Of The University Of Minnesota Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
ES2991089T3 (es) 2017-09-22 2024-12-02 Centre Nat Rech Scient Glicoproteína mutada del virus de la estomatitis vesicular
CN110499297B (zh) * 2019-08-29 2021-07-09 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
WO2022033469A1 (zh) * 2020-08-14 2022-02-17 上海行深生物科技有限公司 重组溶瘤病毒及其构建方法和用途
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
EP4298114A1 (en) 2021-02-26 2024-01-03 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
US12269882B1 (en) 2023-09-25 2025-04-08 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1118403B (de) 1960-01-27 1961-11-30 Hoechst Ag Verfahren zur Gewinnung von antitumorwirksamen Sporen
GB1069144A (en) 1963-07-10 1967-05-17 Merck & Co Inc Method for the treatment of malignant tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
PT713397E (pt) * 1992-03-24 2003-04-30 United Cancer Res Inst Vacina que contem virus vivos
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US7153510B1 (en) * 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
WO1997026904A1 (en) 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
PT1012244E (pt) * 1997-07-11 2007-08-21 Univ Yale ''rabdovírus com revestimentos remanipulados''
HUP0003911A3 (en) * 1997-10-09 2007-11-28 Pro Virus Treatment of neoplasms with viruses
EP1040198B1 (en) * 1997-12-22 2009-12-09 The University Of Tennessee Research Corporation Recombinant rhabdovirus containing a heterologous fusion protein
WO1999045783A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
MXPA00012402A (es) * 1998-06-12 2003-07-14 Sinai School Medicine Metodos y substratos deficientes de interferon, novedosos, para la propagacion de virus.
MXPA01010393A (es) * 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.

Also Published As

Publication number Publication date
CA2386920A1 (en) 2001-03-22
IL148621A (en) 2010-02-17
ATE418341T1 (de) 2009-01-15
NZ517573A (en) 2004-02-27
ES2320239T3 (es) 2009-05-20
HK1044708A1 (en) 2002-11-01
NZ534306A (en) 2005-12-23
WO2001019380A3 (en) 2001-11-22
IL148621A0 (en) 2002-09-12
ES2260057T3 (es) 2006-11-01
CA2386920C (en) 2012-01-24
AU782402B2 (en) 2005-07-28
EP1218019A2 (en) 2002-07-03
DE60026554T2 (de) 2006-09-28
NZ523805A (en) 2004-09-24
EP1716858A2 (en) 2006-11-02
HK1044708B (en) 2006-10-27
JP2004525855A (ja) 2004-08-26
NZ534307A (en) 2005-07-29
EP1218019B1 (en) 2006-03-08
CN1496268A (zh) 2004-05-12
HK1092713A1 (en) 2007-02-16
CN1289098C (zh) 2006-12-13
ATE319460T1 (de) 2006-03-15
AU7588200A (en) 2001-04-17
EP1716858B1 (en) 2008-12-24
DE60026554D1 (de) 2006-05-04
DE60041210D1 (de) 2009-02-05
EP1716858A3 (en) 2007-08-15
JP5060694B2 (ja) 2012-10-31
WO2001019380A2 (en) 2001-03-22
EP1716858B9 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
MXPA02002772A (es) Virus oncolitico.
DE60239394D1 (de) Onkolytische virustherapie
Boga et al. Beneficial actions of melatonin in the management of viral infections: a new use for this “molecular handyman”?
LU93101I2 (fr) Imlygic-talimogene laherparepvec
ATE227133T1 (de) Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
MY141594A (en) 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
NO995263L (no) Konjugater av polyetylenglykol og interferon-<alfa> for terapi av infeksjoner
EP1217891A4 (en) THERAPEUTIC PROCEDURES AND COMPOSITIONS USING VIRUSES FROM THE RECOMBINANT FAMILY OF THE PARAMYXOVIRIDAE
WO2002032942A3 (en) Compositions and methods for modulating rsv infection and immunity
BR0109928A (pt) Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal
Warfel et al. Production and initial characterization of guinea pig interferon
EP0531341A4 (en) Anti-viral therapy
ATE89569T1 (de) Haemoglobin mit reduziertem virusrisiko und dessen herstellung.
Eylan et al. Resistance of aged cells to virus replication
Czarniecki et al. Disparate response of encephalomyocarditis virus and MM virus to interferon in JLS-V9R cells
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE262919T1 (de) Verwendung von il-11 zur verstärkung der zellvermittelten immunität zur behandlung verschiedener viraler und parasitärer infektionen und krebs
DK1250422T3 (da) Myeloid-kolonistimulerende faktor og anvendelser deraf
DK0979093T3 (da) Terapeutisk virusmiddel, hvis udvikling kan standses
Xiao et al. Kinetics of antiviral state in cells activated by interferons in vitro
GB1300567A (en) Therapeutic compositions
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
TW200611905A (en) Macrocyclic compounds as inhibitors of viral replication

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status